Engineered T-Cells Show Promise for Single-Dose Asthma Remission
Recent research has demonstrated that a single infusion of engineered T-cells can achieve lasting asthma remission in mice asthma remission in mice , potentially expanding the indications for cell therapies beyond cancer. Traditionally, cell therapies have shown durable remission in some cancers, but researchers are now exploring their potential for treating non-cancerous diseases. Notably, CAR T-cell therapy has been successful in curing patients with B-cell malignancies, prompting interest in whether similar approaches could work for other conditions. Asthma, a common chronic disease, often involves a type-2 high signature characterized by eosinophilia, immunoglobulin E (IgE) production, bronchial hyperresponsiveness, and mucus hypersecretion. While biologic agents targeting interleukins such as IL-4, IL-5, and IL-13 have been approved for asthma treatment, they require lifelong administration and are neither cost-effective nor curative. This study aimed to develop a treatment that c...